Targeting HER2 in other tumor types

Annals of Oncology

Volumn 12, Issue SUPPL. 1, 2001, Pages

  Scholl, S ^a   Beuzeboc, P ^a   Pouillart, P ^a  

^a INSTITUT CURIE   (France)

Author keywords

Anti HER2 monoclonal antibody; HER2; Predictive marker; Prognostic marker; Therapeutic target

Indexed keywords

CARBOPLATIN; CISPLATIN; DOXORUBICIN; EMODIN; EPIDERMAL GROWTH FACTOR RECEPTOR; GEMCITABINE; GENISTEIN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2; MONOCLONAL ANTIBODY; PACLITAXEL; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLADDER CANCER; BREAST CANCER; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CANCER GROWTH; CANCER HORMONE THERAPY; CELL PROLIFERATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENTIATION; DRUG TARGETING; ENDOMETRIUM CANCER; GENE AMPLIFICATION; GENE OVEREXPRESSION; HEAD AND NECK CANCER; HUMAN; IN VITRO STUDY; LUNG NON SMALL CELL CANCER; METASTASIS; MOUSE; NONHUMAN; ONCOGENE NEU; OSTEOSARCOMA; OVARY CANCER; PANCREAS CANCER; PHASE 2 CLINICAL TRIAL; PHASE 3 CLINICAL TRIAL; PREDICTION; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RANDOMIZED CONTROLLED TRIAL; SALIVARY GLAND CANCER; SOLID TUMOR; SQUAMOUS CELL CARCINOMA; STOMACH CANCER;

EID: 0034871359     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/12.suppl_1.S81     Document Type: Article

References (100)

1. Growth factors and cancer
2. The product of the c-erbB-2 gene: A 185-kilodalton glycoprotein with tyrosine kinase activity
3. Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene
4. The neu oncogene encodes an epidermal growth factor receptor-related protein
5. ErbB-2, the preferred heterodimerization partner of all ErbB receptors, is a mediator of lateral signaling
6. A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor
7. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene
8. Studies of the HER2/neu proto-oncogene in human breast and ovarian cancer
9. Epidermal-growth-factor receptors in human bladder cancer: Comparison of invasive and superficial tumor
10. An immunohistologic evaluation of c-erbB-2 gene product in patients with urinary bladder carcinoma
11. Heterogeneity of erbB-2 gene amplification in bladder cancer
12. Prevalence and clinical significance of HER2/neu, p53 and Rb expression in primary superficial bladder cancer
13. Overexpression of HER2/neu oncogene in pancreatic cancer correlates with shortened survival
14. Overexpression of HER-2/neu oncogene in human pancreatic carcinoma
15. The immunohistochemical expressions of epidermal growth factors, epidermal growth factor receptors and c-erb-B2 oncoprotein in human pancreatic cancer
16. p185neu expression in human lung adenocarcinomas predicts shortened survival
17. The interactive effect of Ras, HER2, P53 and bcl-2 expression in predicting the survival of non-small-cell lung cancer patients
18. Overexpression of the c-erb-B2/neu-encoded p185 protein in primary lung cancer
19. Expression of the neu gene-encoded protein (P185neu) in human non-small-cell carcinomas of the lung
20. The biology of erbB-2/neu/HER-2 and its role in cancer
21. Overexpression of the oncogene c-erbB-2 (HER2/neu) in ovarian cancer: A new prognostic factor
22. HER-2/neu amplification and overexpression in endometrial carcinoma
23. Amplification and overexpression of HER-2/neu (c-erbB2) in endometrial cancers: Correlation with overall survival
24. Frequent amplification of c-erb-B2 (HER-2/neu) oncogene in cervical carcinoma as detected by non-fluorescence in situ hybridisation technique on paraffin sections
25. Expression of the c-erbB-2 gene product (p185) at different stages of neoplastic progression in the colon
26. C-erb B-2 amplification in cystic renal disease
27. HER-2/neu oncogene characterization in head and neck squamous cell carcinoma
28. c-erbB-2 oncogene product staining in gastric adenocarcinoma. An immunohistochemical study
29. Expression of Her2/neu oncogene product p185 in correlation to clinicopathological and prognostic factors of gastric carcinoma
30. Amplification and over-expression of the EGFR and erbB-2 genes in human esophageal adenocarcinomas
31. Amplification of the epidermal growth factor receptor gene, but no evidence of ras mutations in primary esophageal squamous cancers
32. Oncogenes and onco-suppressor gene in adenocarcinoma of the oesophagus
33. Fluorescence in situ hybridization study of HER-2/neu oncogene amplification in prostate cancer
34. c-erbB-2 oncoprotein: A potential biomarker of advanced prostate cancer
35. HER2 overexpression in various tumor types, focussing on its relationship to the development of invasive breast cancer
36. Quantitation of EGFR and c-erbB-2 expression in preinvasive compared to invasive breast cancers
37. Expression of the HER2/neu proto-oncogene in normal human adult and fetal tissues
38. Overexpression of the c-erbB-2 protein in human breast tumor cell lines
39. Amplification and overexpression of the erbB-2 gene in human tumors: Its involvement in tumor development, significance as a prognostic factor, and potential as a target for cancer therapy
40. The HER2 (c-erbB-2) oncogene is frequently amplified in carcinomas of the breast
41. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridisation
42. Expression of ERBB2 in human gastric carcinomas: Relationship between p185ERBB2 expression and the gene amplification
43. Comparative investigation of c-erbB2/neu expression in head and neck tumors and mammary cancer
44. Overexpression of HER-2/neu and its relationship with other prognostic factors changed during progression of in-situ to invasive breast cancer
45. HER-2/neu amplification predicts poor survival in node-positive breast cancer
46. Erb-B2 amplification in breast cancer with a high rate of proliferation
47. Prognostic importance of c-erbB-2 expression in breast cancer
48. Amplification of a novel c-erbB-related gene in a human mammary carcinoma
49. HER-2/neu gene amplification characterized by fluorescence in situ hybridization. Poor prognosis in node-negative breast carcinomas
50. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy
51. Implications of erbB-2 overexpression for basic science and clinical medicine
52. Lack of evidence for the prognostic significance of c-erbB-2 amplification in human breast cancer
53. p53 protein accumulation and response to adjuvant chemotherapy in pre-menopausal women with node-negative early breast cancer
54. Predictive value of c-erbB-2, p53, cathepsin-D and histology of the primary tumor in metastatic breast cancer
55. Should HER2 status be routinely measured for all breast cancer patients?
56. No significant predictive value of c-erbB-2 or p53 expression regarding sensitivity to primary chemotherapy or radiotherapy in breast cancer
57. Lack of c-erb-B2 overexpression predicts better response to dose intensification of anthracycline-based chemotherapy in high-risk breast cancer
58. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu
59. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells
60. Overexpression of c-erbB-2/neu in breast cancer cells confers increased resistance to Taxol via mdr-1-independent mechanisms
61. An overview of monoclonal antibody therapy of cancer
62. Humanization of an anti-p185HER2 antibody for human cancer therapy
63. Differential responses of the human tumor cell lines to anti-p185HER2 monoclonal antibodies
64. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease
65. Addition of Herceptin® (humanized anti-HER2 antibody) to first line chemotherapy for HER2 overexpressing metastatic breast cancer (HER2+/MBC) markedly increases anticancer activity: A randomized multinational III trial
66. Recent cancer trends in the United States
67. United States lung carcinoma incidence trends: Declining for most histologic types among males, increasing among females
68. Cancer of the lung
69. Correlation of intrinsic chemoresistance of non-small-cell lung cancer cell lines with HER-2/neu gene expression but not with ras gene mutations
70. Inhibition of human lung cancer cell line growth by an anti-p185HER2 antibody
71. p185HER2 monoclonal antibody has antiproliferative effects in vitro and sensitizes human breast tumor cells to tumor necrosis factor
72. p185HER2 signal transduction in breast cancer cells
73. Suppressed transformation and induced differentiation of HER-2/neu-overexpressing breast cancer cells by emodin
74. Sensitization of HER-2/neu-overexpressing non-small-cell lung cancer cells to chemotherapeutic drugs by tyrosine kinase inhibitor emodin
75. Enhancement of chemosensitivity by tyrphostin AG825 in high-p185(neu) expressing non-small-cell lung cancer cells
76. Ovarian carcinoma: A multivariate analysis of prognostic factors
77. Overexpression of HER-2/neu is associated with poor survival in advanced epithelial ovarian
78. Overexpression of the oncogene c-erbB-2 (HER2/neu) and response to chemotherapy in patients with ovarian cancer
79. Prognostic significance of HER-2/neu expression in advanced epithelial ovarian cancer: A multivariate analysis
80. c-erbB-2 oncogene expression in ovarian cancer
81. p185c-erbB-2 signaling enhances cisplatin-induced cytotoxicity in human breast carcinoma cells: Association between an oncogenic receptor tyrosine kinase and drug-induced DNA repair
82. A monoclonal antibody against the c-erbB-2 protein enhances the cytotoxicity of cis-diamminedichloroplatinum against human breast and ovarian tumor cell lines
83. Antibody to HER-2/neu receptor blocks DNA repair after cisplatin in human breast and ovarian cancer cells
84. Monoclonal antibody therapy of human cancer: Taking the HER2 protooncogene to the clinic
85. Remission of human breast cancer xenografts on therapy with humanized monoclonal antibody to HER-2 receptor and DNA-reactive drugs
86. New developments in the treatment of gastric carcinoma
87. Surgical treatment of gastric carcinoma
88. Lymphadenectomy in gastric carcinoma - A prospective and prognostic study
89. Expression of c-erbB-2 oncoprotein in gastric carcinoma
90. Evaluation of immunoreactivity for erbB-2 protein as a marker of poor short term prognosis in gastric cancer
91. Therapy of an animal model of human gastric cancer using a combination of anti-erbB-2 monoclonal antibodies
92. In vitro and in vivo anti-tumor effects of a humanised monoclonal antibody against c-erbB-2 product
93. Expression of c-erb-B2 in human head and neck carcinoma
94. c-erb-B2 expression in squamous cell carcinoma of the head and neck
95. Overexpression of HER-2/neu in endometrial cancer is associated with advanced stage disease
96. Amplification and expression of c-erb-B2 oncogene in normal, hyperplastic, and malignant endometria
97. A close correlation between c-erbB-2 gene amplification and local progression in endometrial adenocarcinoma
98. Expression of HER2/erbB-2 correlates with survival in osteosarcoma
99. HER-2/neu expression: A major prognostic factor in endometrial cancer
100. Overexpression of Her-2 in patients with poorly differentiated carcinoma or poorly differentiated adenocarcinoma of unknown primary site